Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06316791
Status:
RECRUITING
Last Update Posted:
2024-03-18
First Post:
2024-03-04
Brief Title:
Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
Sponsor:
Juventas Cell Therapy Ltd
Organization:
Juventas Cell Therapy Ltd
Study Overview
Official Title:
Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Exploratory clinical study of CNCT19 anti CD19 cell therapy in the treatment of refractory autoimmune diseasesTo evaluate the safety and tolerability of CNCT19 in patients with refractory systemic lupus erythematosus lupus nephritis immune thrombocytopenia refractory ANCA-associated vasculitis and refractory dermatomyositis on the basis of standard of care
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None